Syros Pharmaceuticals Inc (SYRS)
0.2743
-0.09
(-23.78%)
USD |
NASDAQ |
Nov 14, 16:00
0.2882
+0.01
(+5.07%)
After-Hours: 18:44
Syros Pharmaceuticals Enterprise Value: -7.537M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -7.537M |
| November 12, 2024 | 56.06M |
| November 11, 2024 | 69.48M |
| November 08, 2024 | 52.84M |
| November 07, 2024 | 51.50M |
| November 06, 2024 | 48.55M |
| November 05, 2024 | 50.69M |
| November 04, 2024 | 48.01M |
| November 01, 2024 | 43.58M |
| October 31, 2024 | 50.42M |
| October 30, 2024 | 50.16M |
| October 29, 2024 | 50.69M |
| October 28, 2024 | 39.42M |
| October 25, 2024 | 36.47M |
| October 24, 2024 | 38.35M |
| October 23, 2024 | 43.18M |
| October 22, 2024 | 49.08M |
| October 21, 2024 | 42.91M |
| October 18, 2024 | 35.40M |
| October 17, 2024 | 35.13M |
| October 16, 2024 | 34.06M |
| October 15, 2024 | 36.20M |
| October 14, 2024 | 35.67M |
| October 11, 2024 | 34.59M |
| October 10, 2024 | 35.13M |
| Date | Value |
|---|---|
| October 09, 2024 | 35.40M |
| October 08, 2024 | 36.47M |
| October 07, 2024 | 34.86M |
| October 04, 2024 | 35.40M |
| October 03, 2024 | 34.86M |
| October 02, 2024 | 34.59M |
| October 01, 2024 | 33.79M |
| September 30, 2024 | 40.50M |
| September 27, 2024 | 15.59M |
| September 26, 2024 | 14.52M |
| September 25, 2024 | 13.44M |
| September 24, 2024 | 13.71M |
| September 23, 2024 | 12.37M |
| September 20, 2024 | 14.25M |
| September 19, 2024 | 15.05M |
| September 18, 2024 | 15.05M |
| September 17, 2024 | 15.59M |
| September 16, 2024 | 15.05M |
| September 13, 2024 | 14.25M |
| September 12, 2024 | 4.061M |
| September 11, 2024 | 5.000M |
| September 10, 2024 | 3.793M |
| September 09, 2024 | 2.185M |
| September 06, 2024 | 2.587M |
| September 05, 2024 | 2.989M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-142.68M
Minimum
Dec 20 2022
749.35M
Maximum
Dec 23 2020
117.22M
Average
83.14M
Median
Jan 05 2024
Enterprise Value Benchmarks
| Baxter International Inc | 27.52B |
| AbbVie Inc | 364.87B |
| Elanco Animal Health Inc | 10.88B |
| Opus Genetics Inc | -12.86M |
| Entrada Therapeutics Inc | 297.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.396M |
| Total Expenses (Quarterly) | 26.18M |
| EPS Diluted (Quarterly) | -0.16 |
| Earnings Yield | -1.12K% |
| Normalized Earnings Yield | -1622.81 |